Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Ann Hematol. 2021 Jul;100(7):1871-1878. doi: 10.1007/s00277-020-04382-y. Epub 2020 Dec 19.

Abstract

Low intake of magnesium has been associated with the occurrence of lymphomas and decreased magnesium levels suppress the cytotoxic function of T cells and natural killer cells in patients with "X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia" (XMEN) syndrome. These cell types are also important mediators of immune-mediated effects after allogeneic hematopoietic stem cell transplantation. Here, we show that high posttransplant magnesium levels independently associate with a lower incidence of relapse, a higher risk of acute graft-versus-host disease, and a higher non-relapse mortality in 368 patients with acute myeloid leukemia from our center. Magnesium serum levels might impact on donor-cell-mediated immune responses in acute myeloid leukemia.

Keywords: Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; GVHD; GVL; Magnesium.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease / blood
  • Graft vs Host Disease / diagnosis
  • Graft vs Leukemia Effect
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Leukemia, Myeloid, Acute / blood
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / therapy*
  • Magnesium / blood*
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Transplantation, Homologous
  • Treatment Outcome
  • Young Adult

Substances

  • Magnesium